Peripheral Nervous System

The Neuromuscular Program was developed in 2012. The program consists of guidance to support Transfusion Medicine screening practice, as well as centralized screening for many neurology conditions, see the PNS Condition List below for further information. 

PNS Condition List

With the expansion of the IVIg Neurology program to include Central Nervous System (CNS) conditions, the Neuromuscular Program was rebranded as the Neurology Program in 2022, where Neuromuscular conditions are now referred to as Peripheral Nervous System (PNS) conditions.

The panel further expanded scope to include the centralized screening of SCIg effective April 1, 2025 to ensure equity and continuity in patient care.

High and Chronic Project for Approved Indications:
The BC Ig Neurology Utilization Panel continues to work with PBCO to optimize the use of Immunoglobulins in the treatment of PNS diseases. To optimize utilization and support best practice, an annual review of patients who have been identified as “high dose or chronic users” with Approved Neurology conditions is performed annually.

High dose users are defined as:

• CIDP/MG patients with more than 1100 g/year (equivalent to >85 g every 4 weeks for 12 months)
• MMN patients with more than 1400 g/year (equivalent to >85 g every 3 weeks for 12 months)

Chronic Users are defined as:

• Patients receiving Ig therapy for more than 3 fiscal years
• With active use in the last fiscal year

Upon completion of each review, recommendation letters will be sent to ordering physicians and transfusion medicine labs. Follow up process:

• High/chronic users deemed as appropriate users will be re-reviewed every 3 years
• High/chronic users deemed as inappropriate or appropriate with recommendations will be reviewed annually

Video: BC Neuromuscular IVIG Task Force: Review of Objectives and Process

To view the video, your computer must be compatible with Mediasite.